ReviewClinicoEconomics and outcomes research : CEOR2017
Drug tendering: drug supply and shortage implications for the uptake of biosimilars.
Review in ClinicoEconomics and outcomes research : CEOR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 62 citations in OpenAlex.
- Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.American journal of clinical dermatology · 2022Trial
- Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake.Pharmaceutical medicine · 2026Review
- Structural drivers of drug shortages and market withdrawal: a longitudinal analysis of the Romanian pharmaceutical market.BMC health services research · 2026Article
- Drug price trends, regional disparities, and supply shortages under China's National Volume-Based Procurement: a nationwide analysis (2018-2024).BMC health services research · 2026Article
- Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Treating rheumatoid arthritis in Zanzibar: a cost effectiveness study comparing conventional, biologic, and targeted-synthetic disease modifying anti-rheumatic drugs.Frontiers in medicine · 2025Article
- Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries.Therapeutic innovation & regulatory science · 2025Article
- Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America.Advances in therapy · 2024Review
- Addressing Challenges in Antibiotic Access: Barriers, Implications and Strategies for Solution.Pharmaceutical medicine · 2024Review
- The impact of Chinese volume-based procurement on pharmaceutical market concentration.Frontiers in pharmacology · 2024Article
- The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.Frontiers in pharmacology · 2024Article
- A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.Frontiers in medicine · 2023Article
- How to select a best-value biological medicine? A practical model to support hospital pharmacists.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2022Article
- Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.Journal of pharmaceutical policy and practice · 2022Article
- Complexity of Drug Substitutions Caused by Drug Tenders: A Mixed-Methods Study in Denmark.Hospital pharmacy · 2021Article
- The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab.Oncology and therapy · 2021Article
- Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.Frontiers in pharmacology · 2021Article
- Drug Shortage: Causes, Impact, and Mitigation Strategies.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the continued increase in global spending on health care, payers have introduced a number of programs, policies, and agreements on pharmaceutical pricing in order to control costs. While incentives to increase generic drug use have achieved significant savings, other cost-containment measures are required. Tendering is a formal procedure to purchase medications using competitive bidding for a particular contract. Although useful for cost containment, tendering can lead to decreased competition in a given market. Consequently, drug shortages can occur, resulting in changes to treatment plans to products that may have lower efficacy and/or an increased risk of adverse effects. Therefore, care must be taken to ensure that tendering does not negatively impact patient care or the health care system. A large and expanding portion of total pharmaceutical expenditure is for biologic therapies. These agents have revolutionized the treatment of many diseases, including cancer and inflammatory conditions; however, patient access to biologic drugs can be limited due to availability, insurance coverage, and cost. As branded biologic therapies reach the end of patent- and data-protection periods, biosimilars are being approved as lower-cost alternatives. Biosimilars are products that are highly similar to the originator product with no clinically meaningful differences in terms of safety, purity, or potency. As more biosimilars receive regulatory approval and adoption increases, these therapies are expected to have an impact on global health care spending and should result in overall savings. However, the use of tendering to maximize the potential benefits of biosimilars has varied across the world. Therefore, the objectives of this review are to examine the drug-tendering process and its implications on drug supply and drug shortages, as well as to describe biosimilars and how tendering may influence their uptake.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.